

# Forschungsprojekte 2015

## Projets de recherche 2015

Unterstützt von: / Soutenus par:



**krebsliga schweiz**  
**ligue suisse contre le cancer**  
**lega svizzera contro il cancro**

<b>Grundlagenforschung / Recherche fondamentale</b>			
<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitel</b>	<b>Dauer (Monate)</b>	<b>Betrag (CHF)</b>
<b>Candidat/e</b>	<b>Numéro du projet Titre du projet</b>	<b>Durée (mois)</b>	<b>Montant (CHF)</b>
<b>Ballmer-Hofer Kurt</b> , Prof. Dr. Forschungsbereich Biologie und Chemie (BIO) Paul Scherrer Institut (PSI) 5232 Villigen	KLS 3569-02-2015 Role of VEGF receptor signalling in primary and metastatic tumour growth and preclinical evaluation of novel allosteric VEGFR-2 inhibitors	6	76 550.–
<b>Bertoni Francesco</b> , Dr. Lymphoma and Genomics Research Program IOR Institute of Oncology Research 6500 Bellinzona	KLS 3580-02-2015 Characterization of FLI1 as an oncogene and therapeutic target in diffuse large B-cell lymphomas	36	359 800.–
<b>Hantschel Oliver</b> , Prof. EPFL SV ISREC UPHAN EPF de Lausanne 1015 Lausanne	KLS 3595-02-2015 Identification and targeting of allosteric regulatory sites in oncogenic cytoplasmic tyrosine kinases	36	374 750.–
<b>Müller Anne</b> , Prof. Dr. Institut für Molekulare Krebsforschung Universität Zürich (UZH) 8057 Zürich	KLS 3612-02-2015 The haematopoietic oncoprotein FoxP1 promotes tumour cell survival in diffuse large B-cell lymphoma: identification of FoxP1 target genes and their relevance for patient stratification and prognostication	18	164 900.–
<b>Theurillat Jean-Philippe</b> , Prof. Dr. IOR Institute of Oncology Research 6500 Bellinzona	KLS 3654-02-2015 Role of TRIM24 in prostate cancer initiation and progression	24	247 200.–

**Klinische Forschung / Recherche clinique**

<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitel</b>	<b>Dauer (Monate)</b>	<b>Betrag (CHF)</b>
<b>Candidat/e</b>	<b>Numéro du projet Titre du projet</b>	<b>Durée (mois)</b>	<b>Montant (CHF)</b>
<b>Ammann Roland A.</b> , Prof. Dr. med. Pediatric Hematology/Oncology Department of Pediatrics University of Bern 3010 Bern	KLS 3645-02-2015 SPOG 2015 FN definition a Swiss Paediatric Oncology Group (SPOG) initiated multicentre open-label randomized controlled multiple crossover non-inferiority trial on safety of a high versus low temperature limit defining fever in paediatric patients with cancer at risk for fever in chemotherapy-induced neutropenia (FN)	48	327 800.–
<b>Güller Ulrich</b> , Prof. Dr. med. Medical Oncology & Hematology Kantonsspital St. Gallen (KSSG) 9007 St. Gallen	KLS 3596-02-2015 SAKK 41/13 adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo- controlled, phase III trial	36	351 650.–
<b>Hemkens Lars</b> , Dr. med. Institute for Clinical Epidemiology and Biostatistics University Hospital Basel 4031 Basel	KLS 3587-02-2015 Clinical decision-making with novel cancer treatments: a meta-epidemiological study on the post-approval generation of clinical evidence	36	166 000.–
<b>Rinaldi Andrea</b> , Dr. Functional Genomics and Lymphoma Group IOR Institute of Oncology Research 6500 Bellinzona	KLS 3636-02-2015 An international phase III multicentre, randomized study with lenalidomide maintenance versus observation after intensified induction regimen containing rituximab followed by high dose chemotherapy and autologous stem cell transplantation as first line treatment in adult patients with advanced mantle cell lymphoma: identification of DNA and methylation changes associated with the clinical outcome	24	115 800.–
<b>Terracciano Luigi M.</b> , Prof. Dr. Molecular Pathology Division University of Basel 4003 Basel	KLS 3639-02-2015 Genetic determinants for progression from cirrhosis to hepatocellular carcinoma	36	365 000.–

<b>Psychosoziale Forschung / Recherche psychosociale</b>			
<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitel</b>	<b>Dauer (Monate)</b>	<b>Betrag (CHF)</b>
<b>Candidat/e</b>	<b>Numéro du projet Titre du projet</b>	<b>Durée (mois)</b>	<b>Montant (CHF)</b>
<b>Barth Jürgen</b> , PD Dr. phil. Institute for Complementary and Integrative Medicine University Hospital Zürich 8006 Zürich	KLS 3564-02-2015 Feasibility of a mind-body medicine mobile app for cancer patients	36	199 550.–

<b>Epidemiologische Forschung / Recherche épidémiologie</b>			
<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitel</b>	<b>Dauer (Monate)</b>	<b>Betrag (CHF)</b>
<b>Candidat/e</b>	<b>Numéro du projet Titre du projet</b>	<b>Durée (mois)</b>	<b>Montant (CHF)</b>
<b>Bochud Murielle</b> , Prof. Dr. med. Division des Maladies Chroniques - Institut Universitaire de Médecine Sociale et Préventive Centre hospitalier universitaire vaudois (CHUV) 1010 Lausanne	KLS 3644-02-2015 Dietary habits, nutrition and risk of late effects after childhood cancer	36	290 200.–

# Stipendien 2015

## Bourses 2015

---

Unterstützt von: / Soutenus par:



**krebsliga schweiz**  
**ligue suisse contre le cancer**  
**lega svizzera contro il cancro**

<b>Gesuchsteller/In</b>	<b>Projektnummer Projekttitel</b>	<b>Dauer (Monate)</b>	<b>Betrag (CHF)</b>
<i>Candidat/e</i>	<i>Numéro du projet Titre du projet</i>	<i>Durée (mois)</i>	<i>Montant (CHF)</i>
<b>Böttcher Steffen</b> , Dr. med. Division of Hematology UniversitätsSpital Zürich (USZ) 8091 Zürich	BIL KLS 3625-02-2015 Generation of mouse models of acute myeloid leukaemia for the identification of genotype-specific therapeutic targets  Destination: Brigham and Women's Hosital, Harvard Medical School, Dana-Farber Cancer Institut, Boston, USA	12	80 800.–
<b>Schubert Adrian Daniel</b> , Dr. med. Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten (HNO) Inselspital Bern 3012 Bern	BIL KLS 3649-02-2015 A prospective study evaluating clinical outcomes using plasma and salivary ctDNA in HNSCC  Destination: Division of Head and Neck Cancer Research, Department of Otolaryngology, Johns Hopkins Cancer Research Build II, Baltimore, USA	18	95 050.–